ReutersBritain's medicines regulator on Friday approved Novavax's COVID-19 vaccine for children aged between 12 and 17 years.
The mRNA vaccines made by Moderna as well as the partnership between Pfizer-BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
Britain in February cleared Novavax's two-dose vaccine, Nuvaxovid, for use in adults.
The mRNA vaccines made by Moderna as well as the partnership between Pfizer-BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
Britain in February cleared Novavax's two-dose vaccine, Nuvaxovid, for use in adults.
Experience Your Economic Times Newspaper, The Digital Way!
Read More News on
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
